Format

Send to

Choose Destination
Hepatology. 2016 Jan;63(1):28-30. doi: 10.1002/hep.28292. Epub 2015 Nov 25.

No scientific basis to restrict 8 weeks of treatment with ledipasvir/sofosbuvir to patients with hepatitis C virus RNA <6,000,000 IU/mL.

Author information

1
Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.
2
Toronto Centre for Liver Disease, University of Toronto, Toronto, Canada.
3
Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD.
4
Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.
PMID:
26474163
PMCID:
PMC4688210
DOI:
10.1002/hep.28292
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center